Hyperkalemia Quality Improvement Program (HK-QIP) Study
← catalyst calendarNCT06884267 · readout in 479 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Other
Enrollment
1,000actual
Sites
49
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-25 | actual | When the study began enrolling |
| Primary completion | 2027-12-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-11 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hyperkalemia
Intervention
- Other: standard hyperkalemia management implementation
Primary outcome
what the primary-completion date above is the date OFThe proportion of patients who achieve RAASi optimizationa with normal sK+ level (3.5 mmol/L ≤ sK+ ≤5.0 mmol/L) after 48 weeks intervention.
measured Week 48
Publications
- PMID 42015032 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed